Leading Players in the Clinical Alarm Management Market – Know the Growth Strategies

According to research report the global clinical alarm management market is expected to reach USD 1,724 million by 2023 from an estimated USD 457 million in 2018, at a CAGR of 30.4%. The clinical alarm management market is rapidly emerging with many regional as well as international companies. In 2017, Koninklijke Philips (Netherlands) and Vocera Communications (US), held a share of approximately 70.0% of the clinical alarm management market. 

The major clinical alarm management vendors include Koninklijke Philips (Netherlands), Vocera Communications (US), Ascom Holdings (Switzerland), Spok, Inc. (US), Bernoulli Enterprise (US), Connexall (Canada), Mobile Heartbeat (US), GE Healthcare (US), Capsule Technologie (US), and Masimo Corporation (US).  These players have adopted various growth strategies, such as product launches and enhancements; acquisitions; expansions; and agreements, partnerships, mergers, and collaborations. Product launches and partnerships and have been the most dominating strategy adopted by major players from 2015 to 2018, which helped them to innovate on their offerings and broaden their customer base.

Download PDF Brchure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69939577

Koninklijke Philips dominated the global clinical alarm management market in 2017. The firm’s clinical alarm management solutions are designed to help caregivers manage alarms and reduce fatigue. Through these solutions the caregivers receive actionable notifications and communicate directly on a smartphone which enables workflow optimization, drives efficiency, and facilitates collaboration among staff. For instance, St. Antonius Hospital (the Netherlands) reduced irrelevant ICU alarms by 40% by utilizing Philips’ clinical alarm management solutions. The company focuses on inorganic growth strategies—such as agreements, collaborations, and partnerships—to strengthen its presence in the clinical alarm management market. For instance, in November 2015, Philips entered into a partnership with Mackenzie Health (Canada) to enable Mackenzie Health to get early and ongoing access to Philips’ latest healthcare technology innovations, including systems interoperability, diagnostic imaging equipment utilization, radiology practice management, patient-centric design, and alarm management.

Vocera Communications is one of the leading players in the clinical alarm management market. The firm has been in the market for about 18 years and offers a diversified range of solutions, including Vocera Alarm Management, Vocera Engage, and Vocera Collaboration Suite among others. Vocera strategically focuses on innovation, which is evident from its investments in R&D (USD 27.7 million (17.0% of sales) in 2017). The firm plans to further invest in R&D activities and improve its R&D capabilities to unlock additional synergies and growth opportunities. This helps the company to constantly develop innovative solutions such as Vocera Alarm Management and Vocera Engage.

Sales to the healthcare market accounted for 98.0%, 97.0% and 98.0% of its overall revenue for the years ended December 31, 2017, 2016, and 2015, respectively.

Structural Heart Devices Market – Edwards Lifesciences and Medtronic are leading players

According to research report the global structural heart devices market is projected to reach USD 15.08 billion by 2023 from USD 9.28 billion in 2018, at a CAGR of 10.2%. Players in this market compete with each other to deliver superior and advanced technologies for heart valve repair and replacement. In 2017, the structural heart devices market was dominated by a few large players, namely, Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), and LivaNova plc (UK).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=161123753

Acquisitions and acquisitions; and partnerships & agreements have been the key strategies adopted by key players between 2015 and 2018. Some of the key players that adopted these strategies are Edwards Lifesciences (US), Medtronic (Ident US), Abbott (US), LivaNova (UK), Micro Interventional Devices (US), Braile Biomédica (Brazil), and CryoLife (US).

Edwards Lifesciences held the leading position in the global structural heart devices market in 2017 on account of its diverse portfolio of transcatheter and surgical heart valves. The company pursues organic as well as inorganic growth strategies, such as product launches For instance, in December 2017, the company acquired Harpoon Medical Inc. (US). The unique beating-heart repair procedure for mitral valve patients of Harpoon Medical complements Edwards’ comprehensives This acquisition was valued at USD 100 million. portfolio of treatments for structural heart disease and reinforcement its commitment to innovation in cardiac surgery.

Download Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161123753

Medtronic held the second position in the structural heart devices market in 2017. The company offers a comprehensive range of transcatheter and surgical heart valve products through its coronal and structural heart division. The key percutaneous surgical products products from the nucleus Evolut PRO system and tissue & mechanical heart valve. To maintain its leading position in the market and increase its customer base, the company focuses on product launches & approvals, partnerships, and expansions. For instance, in 2016, the company partnered with the World Stroke Organization (WSO, Switzerland). Under this partnership, the two organizations will work together to educate, raise awareness, and support the effective management of patients who suffer from strokes.

CryoLife, Inc. (US), Micro Interventional Devices, Inc. (US), Braile Biomédica (Brazil), Lepu Medical Technology (Beijing) Co., Ltd. (China), and TTK Healthcare Limited (India).

Immunoassay Market Size, Share, Trend Forecast by 2023

According to the new market research report  Immunoassay Market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%.

The increasing incidence of chronic and infectious diseases, technological advancements in immunoassays and introduction of novel automated systems, and growth in the biotechnology and biopharmaceutical are are some of the major factors driving the growth of the markets.

By products and services, the reagents and kits segment commanded the largest share of the market in 2017

In 2017, the reagents and kits segment accounted for the largest shares of the market. The large share of this segment can be primarily be. On the basis product and service, this market is classified into reagents and kits. The number of immunoassays being being performed was performed across the globe as a result as a result of the rising incidence of chronicity and infectious diseases.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=436

The chemiluminescence immunoassays (CLIAs) segment led the immunoassays market in 2017

By platform, this market is classified into CLIAs, radioimmunoassays (RIs), colorimetric immunoassays (CIs), fluorescence immunoassays (FIAs), and other platforms. The CLIAs segment accounted for the largest share of the immunoassays in the world. This segment can be attributed to the low cost and high sensitivity of CLIA-based tests.

By technology, the enzyme-linked immunosorbent assays (ELISA) segment accounted for the largest share of the market in 2017

The ELISA assay market is segmented into ELISA, rapid tests, western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR, and other immunoassay technologies. The ELISA segment accounted for the largest number of other groups 2017. The large share of this segment can be attributed to the increasing use of immunoassay test in cancer, infectious diseases, and therapeutic drug level monitoring.

North America held the largest share of the market in 2017

North America, Europe, Asia, Pacific, Latin America, and the Middle East & Africa. North America dominated the market in 2017. The large share of this regional segment is attributed to the increasing incidence of chronic diseases and improved healthcare infrastructure.

Get Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=436

Key players in the immunoassay market include Roche (Switzerland), Abbott Laboratories (US), Siemens (Germany), Danaher Corporation (US), Sysmex Corporation (Japan), bioMérieux (France), Ortho Clinical Diagnostics (US), DiaSorin (Italy) ), QIAGEN (Netherlands), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), Agilent Technologies (US), PerkinElmer (US), Quidel Corporation ( US), Bio-Techne Corporation (US), and Mindray (China).

Precision Medicine Software Market worth $2.0 billion by 2024

According to the new market research report Precision Medicine Software Market is projected to reach USD 2.0 billion by 2024 from USD 1.2 billion in 2019, at a CAGR of 11.5%.
Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine software market.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=247980900
By delivery mode, cloud-based systems are to register the highest CAGR during the forecast period
On the basis of delivery mode, the precision medicine software market is segmented into on-premise and cloud-based systems. The cloud-based segment is expected to register the highest CAGR of the precision medicine software market during the forecast period. Growth in this segment can be attributed to the comparatively lower capital expenses and operational costs incurred in this model, alongside its scalability, flexibility, and affordability. Cloud-based solutions help healthcare organizations share and integrate information from different locations, and these solutions are comparatively affordable to install and maintain than on-premise solutions, which contribute to the high growth and popularity of the cloud-based delivery model.
By application, the oncology segment dominated the precision medicine software market in 2018
By application, the precision medicine software market is segmented into oncology, pharmacogenomics, rare diseases, and other applications. The oncology segment accounted for the largest share of the precision medicine software market in 2018. The large share of this segment can be attributed to the growing prevalence of cancer, rising funding in cancer research, promising applications of precision medicine in oncology research, and increased investments by government organizations in precision medicine software.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247980900
North America dominated the market in 2018
Geographically, the precision medicine software market is divided into North America, Europe, Asia, and the Rest of the World (RoW). North America accounted for the largest share in 2018 owing to factors such as growing investments and favorable initiatives for the implementation of precision medicine software. North America is followed by Europe and Asia. The market in North America is also projected to be the fastest-growing market during the forecast period.
Syapse, Inc. (US), 2bPrecise LLC (Israel), Foundation Medicine, Inc. (US), Fabric Genomics (US), SOPHiA GENETICS SA (Switzerland), PierianDx, Inc. (US), N-of-One, Inc. (US), Human Longevity, Inc. (US), Translational Software, Inc. (US), Sunquest Information Systems Inc. (US), Gene42, Inc. (Canada), LifeOmic Health, LLC (US), NantHealth, Inc. (US), Tempus Labs, Inc. (US), Flatiron Health, Inc. (US), IBM Watson Group (US), and Koninklijke Philips N.V. (Netherlands) are the key players in the precision medicine software market.

Growth in the Genome Editing Market Is Likely To Be Focussed On the North America Region

According to research report the global Genome Engineering Market is projected to be valued at USD 3.19 Billion in 2017 and is expected to grow at a CAGR of 14.5% to reach to USD 6.28 Billion by 2022. Lucrative North America markets to offer significant growth opportunities for the genome editing market in the coming years. This can be attributed to the development of gene therapy, increasing use of genetically modified (GM) crops, and rising availability of research grants and funding in the U.S., and government initiatives and the intensification of genomics R&D in Canada.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=231037000  

Companies in the U.S. are developing their own gene therapies. For instance, in May 2015, Bluebird Bio began seeking approval for LentiGlobin, a gene therapy for beta-thalassemia, a blood disorder. These treatments are expected to be the first gene therapies approved in the U.S. Cold Genesys, Amgen, VBL Therapeutics, Advantagene, and UniQure are other companies developing gene therapies. Additionally, U.S. is the world’s largest producer of GM crops (Source: Worldwatch Institute). According to the Center for Food Safety (Washington, D.C.), in 2015, up to 92% of corn, 94% of soybeans, and 94% of cotton was genetically engineered (GE) in the U.S. Moreover, the adoption of herbicide-resistant corn has also grown significantly, reaching 89% in 2015 (Source: U.S. Department of Agriculture (USDA).

Government institutes like the CDC and the National Human Genome Research Institute (NHGRI) have provided funds and grants to support research in this field. For instance, in November 2014, the CDC funded USD 1.4 million to state health departments in Connecticut, Michigan, Oregon, and Utah to support cancer genomics for cancer diagnosis. Each department will receive USD 325,000 to 350,000 each year for five years (Source: CDC)

Furthermore, NHGRI also funds programs and projects as a part of its strategic plans. Some of the funded programs and projects including USD 1,000 Genome (for the structure of genomes), 1,000 Genomes Project (for the structure of genomes), and The Cancer Genome Atlas (TCGA) (for the biology of diseases. Industry players in the U.S. are focusing on collaboration, acquisition, partnerships, and agreements, among other strategies, to enhance their market shares. This has contributed directly to the overall development—and subsequently, the growth—of the U.S. market. For instance, in March 2016, Thermo Fisher (U.S.) acquired Affymetrix, Inc. (U.S.), a provider of technologies that enable multiplex and parallel analysis of biological systems at the cell, protein, and gene levels. The acquisition integrated Affymetrix’s major product groups into Thermo Fisher Scientific’s existing businesses.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
The Canadian government has undertaken various initiatives to boost the gene engineering market in the country. In July 2016, Genome Canada funded genomic research projects across health, agriculture and agri-food, forestry, fisheries and aquaculture, environmental, energy, and mining, among other sectors. Additionally, Canada initiated a strategic plan towards funding genomics-based downstream research and development (R&D) projects. This includes the Genomic Applications Partnership Program (GAPP), initiated by the Ontario Genomics Institute (OGI). Furthermore, according to the Canadian Cancer Society, 196,900 new cancer cases were diagnosed in 2015, as opposed to 191,300 in 2014. Cancer is the largest cause of mortality in Canada, having caused 78,000 deaths in 2015—30% of the total deaths. The rising incidence of cancer, which will augment the need for diagnostic procedures, is likely to boost the growth of the genome editing market in Canada

Stable Isotope Labeled Compounds Market International Players and Business Insights

According to the recent research report the global stable isotope-labeled compounds market is projected to reach USD 294.2 million by 2022 from USD 254.6 million in 2017, at a CAGR of 2.9% during the forecast period.

The stable isotope-labeled compounds market is emerging and fragmented in nature with various regional and international players. In 2016, Cambridge Isotope Laboratories, Inc. (U.S.) and Merck KGaA (Germany) dominated the stable isotope-labeled compounds market.

Cambridge Isotope Laboratories, Inc. specializes in the process of labeling biochemical and organic compounds with highly enriched, stable (non-radioactive) isotopes of carbon, hydrogen, nitrogen, and oxygen. These products find application in structural biology, proteomics, genomics, molecular biology, metabolic research, clinical and diagnostic research, and ultra-trace environmental analysis. To maintain its leading position and increase its customer base in the stable isotope-labeled compounds market, the company mainly focuses on strategic agreements and product launches. Moreover, the company’s isotope separation facility located in Ohio (U.S.) is the world’s largest carbon-13 and oxygen-18 isotope separation facilities and has the only commercial heavy enrichment columns in the world.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=53034199

Merck KGaA held the second position in the global stable isotope-labeled compounds market in 2016. The company offers stable isotope-labeled compound products through its Life Sciences segment. After the acquisition of Sigma-Aldrich (U.S.) in 2015, the firm became a prominent player in the stable isotope-labeled compounds market. The company offers stable isotope-labeled carbohydrates, amino acids, nucleotides, vitamins among others. Merck KGaA focuses on acquisitions, collaborations, and geographic expansions to strengthen its position in the market. In addition, the presence of a strong distribution and sales network across the globe has enabled this company to maintain its position in the market.

Some of the other players competing in this market are URENCO Limited (U.K.), IsoSciences, LLC (U.S.), Medical Isotopes, Inc. (U.S.), Omicron Biochemicals, Inc. (U.S.), Nordion (Canada) Inc., Trace Sciences International (U.S.), Alsachim (France), Taiyo Nippon Sanso Corporation (Japan), PerkinElmer Inc. (U.S.), and Rotem Industries Israel, Ltd. (Israel).